Last reviewed · How we verify
CNG Chemotherapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
CNG Chemotherapy (CNG Chemotherapy) — Sun Yat-sen University. CNG is a chemotherapy regimen combining multiple cytotoxic agents to inhibit cancer cell proliferation and induce apoptosis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CNG Chemotherapy TARGET | CNG Chemotherapy | Sun Yat-sen University | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CNG Chemotherapy CI watch — RSS
- CNG Chemotherapy CI watch — Atom
- CNG Chemotherapy CI watch — JSON
- CNG Chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). CNG Chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/cng-chemotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing